Sumanta K. Pal: Grateful to the amazing Huntsman Cancer Institute team for drawing me into this important work
Sumanta K. Pal, Vice Chair of Academic Affairs at City of Hope, shared Zeynep Irem Ozay‘s, Postdoctoral Research Fellow at Huntsman Cancer Institute, post on X:
“Grateful to Zeynep Irem Ozay, Neeraj Agarwal, Umang Swami and the amazing Huntsman Cancer Institute team for drawing me into this really important work. Seeing that 38% & 14% of pts receive 2nd and 3rd L tx for kidney cancer highlights the importance of picking the best tx upfront and not ‘saving’ drugs for later.
Matt Campbell in comments on the original post brings up important questions on the ‘why’. It’s disheartening to think that despite the many advances we have made in the pre-treated setting, many patients may not ever receive these modalities.”
Quoting Zeynep Irem Ozay’s post on X, sharing about a recent paper:
“Just in JAMA Network Open
Real world Rx data from >8500 pts with mRCC kidney cancer. After 2018, only 38% and 14% of patients received 2nd and 3rd line Rx respectively. Thanks to my mentors Umang Swami, Sumanta K. Pal, Neeraj Agarwal.”
Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US
Authors: Zeynep Irem Ozay, Yeonjung Jo, Gliceida Galarza Fortuna, et al.
What Patients need to know about Renal Cell Carcinoma? Discover More in Our Articles:
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023